New Market - December 9, 2025
Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing
Cinclus Pharma Holding's drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) for the treatment of gastroesophageal reflux disease (GERD).
Biotech Business - November 24, 2025
Alvotech receives European approval of a biosimilar to Prolia and Xgeva
“This milestone reflects not only the dedication and expertise of our teams, but also the strong partnerships we have built to bring affordable medicines to patients across Europe,” says Robert Wessman, Chairman and Chief Executive Officer of Alvotech.
Biotech Business - November 21, 2025
Alvotech and Advanz Pharma receive marketing approval across the European Economic Area
The European Commission (EC) has granted marketing authorizations in the European Economic Area (EEA) for Gobivaz, Alvotech’s biosimilar to Simponi (golimumab).
MedTech Business - November 6, 2025
Mölnlycke establishes first wound care manufacturing site in China
The manufacturing site, spanning 10,000 m2 is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027.
New Market - November 5, 2025
Moberg Pharma and Karo Healthcare in license agreement
Moberg Pharma has entered into an exclusive licensing agreement with Karo Healthcare regarding the commercialization of MOB-015 (Terclara) in Europe.
Biotech Business - October 14, 2025
First patient treated with BioArctic’s Leqembi in the Nordics
Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment.
